Julie Coleman

2 weeks ago | cnbc.com | Julie Coleman

Stock chart iconBioMarin Pharmaceutical’s year-to-date stock performance. BioMarin Pharmaceutical: “I’m getting tired of the orphan drug model...I don’t think it works now.”Stock chart iconUnion Pacific’s year-to-date stock performance. Union Pacific: “I think it’s a buy...I think it’s a really good stock to own.”Stock chart iconGitLab’s year-to-date stock performance. GitLab: “I was prepared for disappointment and I got it...I just do not want enterprise software.

2 weeks ago | cnbc.com | Julie Coleman

CNBC's Jim Cramer on Wednesday reviewed three sectors where highly-speculative names are gaining traction: space, quantum computing and nuclear power. "I've tried to be skeptical of these three red-hot areas, but as I told you last week, once the thing really takes off, you can't be a scold," he said.

2 weeks ago | cnbc.com | Julie Coleman

CNBC's Jim Cramer on Wednesday said it's necessary for the U.S. to negotiate with countries other than China for rare earth minerals. "We need to make these rare earth deals with the same alacrity that the White House gave out the reciprocal tariffs on 'liberation day.' We need them yesterday," he said. "Then, and only then, will we truly be liberated."China dominates the global market for these critical minerals, producing about 60% and processing almost 90%, CNBC reported.

2 weeks ago | nbcnewyork.com | Julie Coleman

• It's that time again! "Mad Money" host Jim Cramer rings the lightning round bell, which means he's giving his answers to callers' stock questions at rapid speed. Joby Aviation: "...Joby is good, and I'm going with it."Arm: "You're in good shape. That's Rene Haas...He is a partner of Nvidia."Papa John's: "I think it's a wait and see situation with Penegor...at Papa John's. So, I'm not going there yet.

2 weeks ago | cnbc.com | Julie Coleman

watch nowCNBC's Jim Cramer on Tuesday said he thinks it's necessary to review stocks that have captured the attention of the younger investors, but aren't always highlighted by Wall Street analysts. "I think relevance dictates that we cover the companies that are treated as irrelevant or even pariahs by the gray beards around here," he said. "It isn't true that no one cares. I fear everyone cares, except those of us on Wall Street.